Articles By Matthew Pillar

  1. Inside The Allogeneic NK Cell Therapy Effort 3/21/2022

    With its genetically engineered induced pluripotent stem cell-derived allogeneic natural killer cell technology, Shoreline Biosciences aims to overcome what Chairman and CEO Kleanthis Xanthopoulos calls the tallest barrier in the space: patient accessibility.

  2. Biotech Leader, Kyiv Native Rallies Support For Ukraine 3/15/2022

    Ukraine-born Ivan Liachko, Ph.D. is Co-founder & CEO of Seattle-based Phase Genomics. He’s rallying his biotech peers to follow the simple, yet powerful example he and his employees have set to aid humanitarian efforts in Ukraine.

  3. What's A “Hybrid Externalized” Manufacturing Model? 3/10/2022

    Anthos Therapeutics’ phase 2 antibody candidate abelacimab could dramatically improve the way clinicians treat very common, high-risk arterial and venous thromboembolic events. The company is exercising manufacturing creativity to maintain clinical supply. Anthos CEO John Glasspool shares on the Anthos approach to outsourcing. 

  4. Leading Your Biotech Through A Beating 3/9/2022

    In a suddenly bearish market for biotechs, there’s little solace in the fact that you’re not facing the hurdles alone. Real peace is reserved for those prepared to clear them. Portage Biotech leader Ian Walters shares insight into his company's formula for weathering stormy markets.

  5. Public Health Preparedness: Why Public Dollars Must Prime Private Investment 3/7/2022

    The private equity model isn’t equipped to fund biotechs interested in preventing—or addressing— the next pandemic. Three experts weigh in on how public/private partnerships should work to unlock emerging biotech innovation in a public health emergency.

  6. Biotech Capital Markets: Why Discernment Is The Word Of The Day 2/28/2022

    Life sciences finance expert Allan Shaw waxes on the sobering of biopharma capital markets, offering his view of what’s to come and suggestions for the leaders of emerging biotech companies.

  7. Why Locus Biosciences Built A Bacteriophage Factory 2/25/2022

    To address a glaring problem in modern medicine, Locus Biosciences co-founder and CEO Paul Garofolo says he had no choice but to build a GMP manufacturing facility that was up to the task—and the risk.

  8. Regenerating The Vasculature With Bioengineered Human Tissue 2/23/2022

    With two phase 3 trials resuting in its bioengineered blood vessels being implanted in some 460 human patients, regenerative medicine pioneer Humacyte is finding its footing in the $150 billion vascular repair, reconstruction, and replacement market. Now it's preparing to reinvent treatment for Type 1 Diabetes.

  9. A Drug Discovery Alliance For The Ages 2/14/2022

    With the renewal of their Collaborative Research Agreement, the La Jolla Institute for Immunology and Kyowa Kirin North America extended a more than 30-year partnership that continues to bear fruit. As many good and longstanding friendships do, it all started with beer. Here’s why the collaboration stands the test of time.

  10. Why One Biopharma Simultaneously Built Two CAR T Manufacturing Facilities On Two Separate Continents During A Pandemic 2/11/2022

    Cellectis SVP of U.S. Manufacturing and Site Head Steve Doares joined the company as it kicked off simultaneous construction of manufacturing plants in Raleigh and Paris—and just as the pandemic began wreaking havoc on biopharmaceutical supply chains. He lived to tell us about it.